|
1
|
Risk factors for Toxoplasma gondii infection in mothers of infants with congenital toxoplasmosis: Implications for prenatal management and screening.
|
Am J Obstet Gynecol
|
2005
|
2.66
|
|
2
|
Unrecognized ingestion of Toxoplasma gondii oocysts leads to congenital toxoplasmosis and causes epidemics in North America.
|
Clin Infect Dis
|
2011
|
1.87
|
|
3
|
Identification of T. gondii epitopes, adjuvants, and host genetic factors that influence protection of mice and humans.
|
Vaccine
|
2010
|
1.61
|
|
4
|
Toxoplasma gondii tachyzoite-bradyzoite interconversion.
|
Trends Parasitol
|
2002
|
1.58
|
|
5
|
NALP1 influences susceptibility to human congenital toxoplasmosis, proinflammatory cytokine response, and fate of Toxoplasma gondii-infected monocytic cells.
|
Infect Immun
|
2010
|
1.46
|
|
6
|
Evolutionary origins of the eukaryotic shikimate pathway: gene fusions, horizontal gene transfer, and endosymbiotic replacements.
|
Eukaryot Cell
|
2006
|
1.44
|
|
7
|
Neurological and behavioral abnormalities, ventricular dilatation, altered cellular functions, inflammation, and neuronal injury in brains of mice due to common, persistent, parasitic infection.
|
J Neuroinflammation
|
2008
|
1.41
|
|
8
|
P2X7 receptor-mediated killing of an intracellular parasite, Toxoplasma gondii, by human and murine macrophages.
|
J Immunol
|
2010
|
1.33
|
|
9
|
Genetic and epigenetic factors at COL2A1 and ABCA4 influence clinical outcome in congenital toxoplasmosis.
|
PLoS One
|
2008
|
1.32
|
|
10
|
Toxoplasmosis-associated neovascular lesions treated successfully with ranibizumab and antiparasitic therapy.
|
Arch Ophthalmol
|
2008
|
1.30
|
|
11
|
Identification of a sporozoite-specific antigen from Toxoplasma gondii.
|
J Parasitol
|
2011
|
1.28
|
|
12
|
The shikimate pathway and its branches in apicomplexan parasites.
|
J Infect Dis
|
2002
|
1.25
|
|
13
|
Severe congenital toxoplasmosis in the United States: clinical and serologic findings in untreated infants.
|
Pediatr Infect Dis J
|
2011
|
1.25
|
|
14
|
Clinical manifestations of ocular toxoplasmosis.
|
Ocul Immunol Inflamm
|
2011
|
1.13
|
|
15
|
Novel triazine JPC-2067-B inhibits Toxoplasma gondii in vitro and in vivo.
|
PLoS Negl Trop Dis
|
2008
|
1.10
|
|
16
|
Impact of visual impairment on measures of cognitive function for children with congenital toxoplasmosis: implications for compensatory intervention strategies.
|
Pediatrics
|
2006
|
1.10
|
|
17
|
Maternal serologic screening to prevent congenital toxoplasmosis: a decision-analytic economic model.
|
PLoS Negl Trop Dis
|
2011
|
1.09
|
|
18
|
Expression, purification and crystallization of the Plasmodium falciparum enoyl reductase.
|
Acta Crystallogr D Biol Crystallogr
|
2003
|
1.09
|
|
19
|
Longitudinal study of new eye lesions in treated congenital toxoplasmosis.
|
Ophthalmology
|
2007
|
1.09
|
|
20
|
Novel N-benzoyl-2-hydroxybenzamide disrupts unique parasite secretory pathway.
|
Antimicrob Agents Chemother
|
2012
|
1.07
|
|
21
|
Genetic analysis of influences on survival following Toxoplasma gondii infection.
|
Int J Parasitol
|
2002
|
1.04
|
|
22
|
Towards an immunosense vaccine to prevent toxoplasmosis: protective Toxoplasma gondii epitopes restricted by HLA-A*0201.
|
Vaccine
|
2010
|
1.04
|
|
23
|
Oral oocyst-induced mouse model of toxoplasmosis: effect of infection with Toxoplasma gondii strains of different genotypes, dose, and mouse strains (transgenic, out-bred, in-bred) on pathogenesis and mortality.
|
Parasitology
|
2011
|
1.02
|
|
24
|
Longitudinal study of new eye lesions in children with toxoplasmosis who were not treated during the first year of life.
|
Am J Ophthalmol
|
2008
|
1.00
|
|
25
|
Lipidomic analysis of Toxoplasma gondii reveals unusual polar lipids.
|
Biochemistry
|
2007
|
1.00
|
|
26
|
Studies of Toxoplasma gondii and Plasmodium falciparum enoyl acyl carrier protein reductase and implications for the development of antiparasitic agents.
|
Acta Crystallogr D Biol Crystallogr
|
2007
|
0.98
|
|
27
|
Cataracts in congenital toxoplasmosis.
|
J AAPOS
|
2007
|
0.98
|
|
28
|
In vitro correlates of Ld-restricted resistance to toxoplasmic encephalitis and their critical dependence on parasite strain.
|
J Immunol
|
2002
|
0.97
|
|
29
|
T. gondii RP promoters & knockdown reveal molecular pathways associated with proliferation and cell-cycle arrest.
|
PLoS One
|
2010
|
0.96
|
|
30
|
Evidence for mitochondrial-derived alternative oxidase in the apicomplexan parasite Cryptosporidium parvum: a potential anti-microbial agent target.
|
Int J Parasitol
|
2004
|
0.95
|
|
31
|
Human immunome, bioinformatic analyses using HLA supermotifs and the parasite genome, binding assays, studies of human T cell responses, and immunization of HLA-A*1101 transgenic mice including novel adjuvants provide a foundation for HLA-A03 restricted CD8+T cell epitope based, adjuvanted vaccine protective against Toxoplasma gondii.
|
Immunome Res
|
2010
|
0.95
|
|
32
|
Molecular target validation, antimicrobial delivery, and potential treatment of Toxoplasma gondii infections.
|
Proc Natl Acad Sci U S A
|
2012
|
0.95
|
|
33
|
Host genetic and epigenetic factors in toxoplasmosis.
|
Mem Inst Oswaldo Cruz
|
2009
|
0.95
|
|
34
|
Toxoplasma gondii HLA-B*0702-restricted GRA7(20-28) peptide with adjuvants and a universal helper T cell epitope elicits CD8(+) T cells producing interferon-γ and reduces parasite burden in HLA-B*0702 mice.
|
Hum Immunol
|
2011
|
0.94
|
|
35
|
The unusual mitochondrial compartment of Cryptosporidium parvum.
|
Trends Parasitol
|
2005
|
0.93
|
|
36
|
Triazine Inhibits Toxoplasma gondii tachyzoites in vitro and in vivo.
|
Antimicrob Agents Chemother
|
2005
|
0.92
|
|
37
|
Salicylanilide inhibitors of Toxoplasma gondii.
|
J Med Chem
|
2012
|
0.87
|
|
38
|
Immunogenetics of Toxoplasma gondii informs vaccine design.
|
Trends Parasitol
|
2010
|
0.84
|
|
39
|
Subcellular localization and dynamics of a digalactolipid-like epitope in Toxoplasma gondii.
|
J Lipid Res
|
2008
|
0.84
|
|
40
|
Design, synthesis, and biological activity of diaryl ether inhibitors of Toxoplasma gondii enoyl reductase.
|
Bioorg Med Chem Lett
|
2013
|
0.84
|
|
41
|
Impaired innate immunity in mice deficient in interleukin-1 receptor-associated kinase 4 leads to defective type 1 T cell responses, B cell expansion, and enhanced susceptibility to infection with Toxoplasma gondii.
|
Infect Immun
|
2012
|
0.83
|
|
42
|
Expression, purification and preliminary crystallographic analysis of the Toxoplasma gondii enoyl reductase.
|
Acta Crystallogr Sect F Struct Biol Cryst Commun
|
2006
|
0.83
|
|
43
|
Spiroindolone that inhibits PfATPase4 is a potent, cidal inhibitor of Toxoplasma gondii tachyzoites in vitro and in vivo.
|
Antimicrob Agents Chemother
|
2013
|
0.82
|
|
44
|
Synthesis, biological evaluation, and structure-activity relationships of N-benzoyl-2-hydroxybenzamides as agents active against P. falciparum (K1 strain), Trypanosomes, and Leishmania.
|
J Med Chem
|
2012
|
0.80
|
|
45
|
Chorioretinal lesions in mothers of children with congenital toxoplasmosis in the National Collaborative Chicago-based, Congenital Toxoplasmosis Study.
|
Sci Med (Porto Alegre)
|
2010
|
0.79
|
|
46
|
Modification of triclosan scaffold in search of improved inhibitors for enoyl-acyl carrier protein (ACP) reductase in Toxoplasma gondii.
|
ChemMedChem
|
2013
|
0.77
|
|
47
|
Discrimination of potent inhibitors of Toxoplasma gondii enoyl-acyl carrier protein reductase by a thermal shift assay.
|
Biochemistry
|
2013
|
0.77
|
|
48
|
Rapid discovery of inhibitors of Toxoplasma gondii using hybrid structure-based computational approach.
|
J Comput Aided Mol Des
|
2011
|
0.76
|
|
49
|
Development of a triclosan scaffold which allows for adaptations on both the A- and B-ring for transport peptides.
|
Bioorg Med Chem Lett
|
2013
|
0.76
|
|
50
|
Spinal Cord Lesions in Congenital Toxoplasmosis Demonstrated with Neuroimaging, Including Their Successful Treatment in an Adult.
|
J Neuroparasitology
|
2012
|
0.75
|